Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Published ADAPT Results Further Support Medtronic’s Highly Anticipated 780G

Executive Summary

Ohad Cohen, director of medical affairs for Medtronic Diabetes EMEA, talked to Medtech Insight about the published results from the ADAPT trial, which showed that Medtronic’s advanced hybrid closed loop insulin delivery technology provides better glycemic control than standard therapies.

You may also be interested in...



UK To Fund ‘Artificial Pancreas’ Technology, But Only For Companies That Cut Prices

The UK’s health technology assessment organization is in favor of funding hybrid closed loop systems for certain people with type 1 diabetes, but only if companies agree to provide such products at more “cost-effective” prices.

Bigfoot Looks To Unlock More Effective Treatments For Type II Diabetics

Bigfoot Biomedical’s Unity system pairs continuous glucose monitoring with smart insulin pen caps, giving patients recommendations on insulin dosing. Because patient interaction is involved, Bigfoot Biomedical can deliver insulin pump-like results to pump-ineligible type II diabetics.

Class-Action Suit Alleges Medtronic’s Rosy Forecast For MiniMed780G Misled Investors

The lawsuit says that Medtronic continued to predict that the new insulin pump would be FDA-approved shortly, even as other regulatory issues and recalls in the diabetes division made that less likely.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT145803

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel